Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07516392 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of a Polygenic Risk Score to Predict the Risk of Pancreatic Ductal Adenocarcinoma

Study acronym: PRE-PDAC
StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 8, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This case-control study aims to evaluate the role of a polygenic risk score in predicting the risk of pancreatic ductal adenocarcinoma (PDAC). The study will compare genetic risk profiles between individuals with PDAC and controls without the disease in order to assess whether a polygenic risk score may help identify individuals at higher risk. The findings may contribute to improving risk stratification and supporting future strategies for early identification and prevention of pancreatic cancer.
Trial Details
NCT Number NCT07516392
Lead Sponsor Catholic University of the Sacred Heart
Conditions
(from sponsor)		 Pancreatic Ductal Adenocarcinoma (mPDAC)
Related terms Genetic Predisposition to Disease, Genetic Risk Score, Pancreatic Neoplasms
Enrollment 1,140 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov